OncoMatch/Clinical Trials/NCT05317858
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Is NCT05317858 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for brain tumor.
Treatment: Blood Brain Barrier Opening - Oncology · Pembrolizumab · Atezolizumab · Cemiplimab · Nivolumab · Iptilimumab — The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Glioblastoma
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St. Joseph's Hospital and Medical Center · Phoenix, Arizona
- Miami Cancer Institute at Baptist Health · Miami, Florida
- Moffitt Cancer Center · Tampa, Florida
- University of Maryland · Baltimore, Maryland
- Atrium Health Wake Forest Baptist · Winston-Salem, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05317858 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify